Pregnancy outcomes following self-reported and objective-measured exposure to oral preexposure prophylaxis in South Africa
- PMID: 37720980
- PMCID: PMC10715696
- DOI: 10.1097/QAD.0000000000003729
Pregnancy outcomes following self-reported and objective-measured exposure to oral preexposure prophylaxis in South Africa
Abstract
Objective: To compare pregnancy outcomes using self-reported and objective levels of intracellular tenofovir diphosphate (TFV-DP) in pregnant women using preexposure prophylaxis (PrEP).
Design: We enrolled pregnant women >15 years without HIV at first antenatal care visit in an observational cohort study to compare pregnancy outcomes by PrEP use.
Methods: Exposure defined as: any PrEP use [tenofovir disoproxil and emtricitabine (TDF/FTC]) prescription + reported taking PrEP], or objectively-measured TFV-DP in dried blood spots in PrEP-using pregnant women. The primary outcome was a composite of pregnancy loss, preterm birth (<37weeks), low birthweight (<2500 g), small for gestational age ([SGA] ≤ tenth percentile), or neonatal death. Multivariable logistic regression models evaluated individual and composite adverse outcomes by self-reported or objectively measured PrEP use adjusting for age, gestational age, gravidity and socio-economic status.
Results: Between August 19 and February 23, we followed 1195 pregnant women and ascertained 1145 pregnancy outcomes (96%); 72% ( n = 826) reported taking PrEP while pregnant, 16% did not take PrEP ( n = 178), 12% were unconfirmed ( n = 141). Overall, 94.5% ( n = 1082) had singleton live births with a median birthweight of 3.2 kg [interquartile range (IQR) = 2.9-3.5], with no difference in pregnancy loss between self-reported PrEP exposed vs. unexposed [4.0 vs. 5.6%; adjusted odds ratio (aOR) = 0.65, 95% confidence interval (CI) = 0.32-1.47]. Composite adverse outcomes did not differ by reported PrEP use (20% for both groups; aOR = 1.07, 95% CI = 0.71-1.63). Comparing objective PrEP use (any TFV-DP vs. no TFV-DP or not on PrEP), adverse outcomes did not differ (aOR = 0.64, 95% CI = 0.39-1.04), nor did other outcomes including preterm birth nor SGA.
Conclusions: Pregnancy outcomes did not differ by PrEP exposure (self-reported or objective), suggesting real-world efficacy that TDF/FTC as PrEP is safe in pregnancy.
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
There are no conflicts of interest.
Figures
Similar articles
-
Pregnancy and neonatal safety outcomes of timing of initiation of daily oral tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, randomised, non-inferiority trial.Lancet HIV. 2023 Mar;10(3):e154-e163. doi: 10.1016/S2352-3018(22)00369-1. Epub 2023 Feb 3. Lancet HIV. 2023. PMID: 36746169 Clinical Trial.
-
Adherence challenges with daily oral pre-exposure prophylaxis during pregnancy and the postpartum period in South African women: a cohort study.J Int AIDS Soc. 2022 Dec;25(12):e26044. doi: 10.1002/jia2.26044. J Int AIDS Soc. 2022. PMID: 36480171 Free PMC article.
-
Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.JAMA. 2014 Jul 23-30;312(4):362-71. doi: 10.1001/jama.2014.8735. JAMA. 2014. PMID: 25038355 Free PMC article. Clinical Trial.
-
Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding.AIDS. 2017 Jan 14;31(2):213-232. doi: 10.1097/QAD.0000000000001313. AIDS. 2017. PMID: 27831952 Review.
-
Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?Curr Opin HIV AIDS. 2016 Jan;11(1):49-55. doi: 10.1097/COH.0000000000000209. Curr Opin HIV AIDS. 2016. PMID: 26633640 Free PMC article. Review.
Cited by
-
In-utero exposure to tenofovir disoproxil fumarate pre-exposure prophylaxis and growth metrics in HIV unexposed breastfed infants in South Africa: a post hoc analysis of the CAP 016 PrEP in pregnancy RCT.Front Pediatr. 2024 Aug 9;12:1447173. doi: 10.3389/fped.2024.1447173. eCollection 2024. Front Pediatr. 2024. PMID: 39184858 Free PMC article.
-
Pharmacovigilance in Pregnancy Studies, Exposures and Outcomes Ascertainment, and Findings from Low- and Middle-Income Countries: A Scoping Review.Drug Saf. 2024 Oct;47(10):957-990. doi: 10.1007/s40264-024-01445-1. Epub 2024 Jun 21. Drug Saf. 2024. PMID: 38907172 Free PMC article. Review.
References
-
- Thomson KA, Hughes J, Baeten JM, John-Stewart G, Celum C, Cohen CR, et al. . Increased risk of HIV acquisition among women throughout pregnancy and during the postpartum period: a prospective per-coital-act analysis among women with HIV-infected partners. J Infect Dis 2018; 218:16–25. - PMC - PubMed
-
- Dinh TH, Delaney KP, Goga A, Jackson D, Lombard C, Woldesenbet S, et al. . Impact of maternal HIV seroconversion during pregnancy on early mother to child transmission of HIV (MTCT) measured at 4–8 weeks postpartum in South Africa 2011–2012: a national population-based evaluation. PLoS One 2015; 10:e0125525. - PMC - PubMed
-
- UNAIDS. Start free stay free AIDS free. Geneva, Switzerland: UNAIDS; 2019.
-
- UNAIDS. Improving UNAIDS’ paediatric and adolescent estimates. 2020. Available at: https://www.unaids.org/sites/default/files/media_asset/improving-unaids-... [Accessed 6 February 2023].
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous